Osteopore Valuation
Is OSX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of OSX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate OSX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate OSX's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OSX?
Key metric: As OSX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is OSX's PS Ratio? | |
|---|---|
| PS Ratio | 1.6x |
| Sales | AU$2.70m |
| Market Cap | AU$4.28m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.1x |
| Enterprise Value/EBITDA | -1.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does OSX's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.9x | ||
VIP VIP Gloves | 0.2x | n/a | AU$2.4m |
VTI Visioneering Technologies | 0.6x | n/a | AU$7.7m |
NXS Next Science | 1.2x | 30.6% | AU$41.6m |
LDX Lumos Diagnostics Holdings | 1.4x | n/a | AU$24.6m |
OSX Osteopore | 1.6x | n/a | AU$4.3m |
Price-To-Sales vs Peers: OSX is expensive based on its Price-To-Sales Ratio (1.6x) compared to the peer average (1.1x).
Price to Sales Ratio vs Industry
How does OSX's PS Ratio compare vs other companies in the AU Medical Equipment Industry?
Price-To-Sales vs Industry: OSX is good value based on its Price-To-Sales Ratio (1.6x) compared to the Australian Medical Equipment industry average (3.1x).
Price to Sales Ratio vs Fair Ratio
What is OSX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.6x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate OSX's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Doctor Care Anywhere Group
AU$25.3m
Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.
DOC
AU$0.07
7D
4.5%
1Y
45.8%
CardieX
AU$32.4m
Engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific.
CDX
AU$0.11
7D
-24.1%
1Y
n/a
Cogstate
AU$170.8m
A neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research.
CGS
AU$0.99
7D
4.2%
1Y
-35.5%